For example, there is compelling evidence for the utility of PARP inhibitors in ovarian cancers in the absence of BRCA mutations (germline or somatic), presumably resulting from other molecular deficiencies in DNA repair. This evidence concerns the gene PARP1 and ovarian cancer.